title: Proteinase-activated receptor 2 is an anti-inflammatory signal for colonic lamina propria lymphocytes in a mouse model of colitis.
abstract: The proteinase-activated receptor 2 (PAR-2) is a member of a family of G protein-coupled receptors for proteases. Proteases cleave PARs within the extracellular N-terminal domains to expose tethered ligands that bind to and activate the cleaved receptors. PAR-2 is highly expressed in colon in epithelial and neuronal elements. In this study we show that PAR-2 activation prevents the development and induces healing of T helper cell type 1-mediated experimental colitis induced by intrarectal administration of 2,4,6-trinitrobenzene sulfonic acid (TNBS) in mice. A role for PAR-2 in the protection against colon inflammation was explored by the use of SLIGRL-NH(2), a synthetic peptide that corresponds to the mouse tethered ligand exposed after PAR-2 cleavage. TNBS-induced colitis was dose-dependently reduced by the administration of SLIGRL-NH(2), whereas the scramble control peptide, LSIGRL-NH(2), was uneffective. This beneficial effect was reflected by increased survival rates, improvement of macroscopic and histologic scores, decrease in mucosal content of T helper cell type 1 cytokines, protein, and mRNA, and a diminished myeloperoxidase activity. SLIGRL-NH(2), but not the scramble peptide, directly inhibited IFN-gamma secretion and CD44 expression on lamina propria T lymphocytes. Protection exerted by PAR-2 in TNBS-treated mice was reverted by injecting mice with a truncated form of calcitonin gene-related peptide and by sensory neurons ablation with the neurotoxin capsaicin. Collectively, these studies show that PAR-2 is an anti-inflammatory receptor in the colon and suggest that PAR-2 ligands might be effective in the treatment of inflammatory bowel diseases.
authors.affiliation: Clinica di Gastroenterologia ed Endoscopia Digestiva, Dipartimento di Medicina Clinica, Patologia Univesita di Perugia, Perugia 06122, Italy. fiorucci@unipg.it
authors.forename: S
authors.initials: S
authors.lastname: Fiorucci
authors.forename: A
authors.initials: A
authors.lastname: Mencarelli
authors.forename: B
authors.initials: B
authors.lastname: Palazzetti
authors.forename: E
authors.initials: E
authors.lastname: Distrutti
authors.forename: N
authors.initials: N
authors.lastname: Vergnolle
authors.forename: M D
authors.initials: MD
authors.lastname: Hollenberg
authors.forename: J L
authors.initials: JL
authors.lastname: Wallace
authors.forename: A
authors.initials: A
authors.lastname: Morelli
authors.forename: G
authors.initials: G
authors.lastname: Cirino
mesh_terms: D000818:Animals; D015740:Calcitonin Gene-Related Peptide / Q000494:pharmacology; D002211:Capsaicin / Q000494:pharmacology; D002478:Cells, Cultured; D003092:Colitis / Q000139:chemically induced / Q000276:immunology* / Q000473:pathology / Q000517:prevention & control; D003106:Colon / Q000166:cytology / Q000276:immunology*; D004195:Disease Models, Animal; D015536:Down-Regulation; D004789:Enzyme Activation; D018960:Hyaluronan Receptors / Q000096:biosynthesis; D007371:Interferon-gamma / Q000096:biosynthesis; D018664:Interleukin-12 / Q000096:biosynthesis; D007376:Interleukin-2 / Q000096:biosynthesis; D051379:Mice; D008807:Mice, Inbred BALB C; D009842:Oligopeptides / Q000494:pharmacology; D010446:Peptide Fragments / Q000494:pharmacology; D044464:Receptor, PAR-2; D018179:Receptors, Thrombin / Q000276:immunology* / Q000378:metabolism; D013601:T-Lymphocytes / Q000166:cytology / Q000187:drug effects / Q000276:immunology*; D014302:Trinitrobenzenesulfonic Acid / Q000009:adverse effects
chemical_list: D018960:Hyaluronan Receptors; D007376:Interleukin-2; D009842:Oligopeptides; D010446:Peptide Fragments; D044464:Receptor, PAR-2; D018179:Receptors, Thrombin; C112356:seryl-leucyl-isoleucyl-glycyl--arginyl-leucinamide; C058636:calcitonin gene-related peptide (8-37); D018664:Interleukin-12; D007371:Interferon-gamma; D014302:Trinitrobenzenesulfonic Acid; D015740:Calcitonin Gene-Related Peptide; D002211:Capsaicin